[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rfa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rfa":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640536","eus-guided-ablation-rfa-and-mwa-for-pancreatic-and-other-gastrointestinal-lesions-registry-100640536",false,"NCT07625189","EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions Registry","Prospective Observational Registry of EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions","Inclusion Criteria:\n\n* Adults ≥ 18 years of age.\n* Diagnosis of a pancreatic premalignant lesion or malignancy, and other gastrointestinal or hepatobiliary lesion for which EUS-guided ablation is planned as part of standard clinical care.\n* At least one clinically identified target lesion for which RFA or MWA is performed.\n\nExclusion Criteria:\n\n* In the judgment of the treating clinician, inclusion in the registry would not be appropriate\n* The individual is expected to be unable to complete routine clinical follow-up.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","1 Year","OBSERVATIONAL","This is a single-center, investigator-initiated, prospective observational registry that will collect longitudinal clinical data on adult patients (≥18 years) undergoing endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) or microwave ablation (MWA) for pancreatic and other gastrointestinal\u002Fhepatobiliary lesions as part of routine clinical care. The registry will not alter standard-of-care management. Data will be abstracted from the medical record and routine clinical systems. Primary outcomes include change in target lesion size on clinically obtained imaging and overall survival following ablation. Secondary outcomes include changes in tumor biomarkers, adverse events, non-target lesion changes, and patient-reported symptoms.",[25,26,27,28,29],"RFA","Microwave Ablation","Pancreatic Lesion","Gastrointestinal Lesions","Ablation Techniques","RECRUITING","2026-05-30",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2026-03-10",{"date":38,"type":20},"2028-03",{"name":40,"class":41},"West Virginia University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100633750","post-market-registry-of-transbronchial-cryo-assisted-rfa-during-routine-standard-bronchoscopic-tumor-stagng-and-resection-100633750","NCT07530744","Post-Market Registry of Transbronchial Cryo-assisted RFA During Routine Standard Bronchoscopic Tumor Stagng and Resection","Cronos","Inclusion Criteria:\n\n* Solitary nodule ≤ 2.5 cm\n* Candidate for diagnostic bronchoscopy \\& LN staging\n* Eligible for surgical resection\n* Histologically proven lung cancer\n* ≥20 mm margin to pleura\u002Fvessels\u002Fbronchi\n* Signed informed consent, age ≥18 y.\n\nExclusion Criteria:\n\n* Pregnancy\u002Fnursing\n* central tumours abutting vital structures\n* thoracic electronic implants\n* uncorrectable coagulopathy or platelets ≤50 × 10⁹\u002FL\n* severe uncontrolled comorbidities or infection; prior SBRT to zone\n* recent investigational therapy (\\\u003C30 d)\n* atelectasis\u002Fobstructive pneumonitis\u002Feffusion\u002Ffibrosis\n* investigator-determined risk.",{"count":51,"type":20},20,"INTERVENTIONAL",[54],"NA","In order to secure the diagnosis of lung cancer, the investigator will perform a bronchoscopy in order to take tissue samples. These samples will be analyzed in the pathology. This is the routine standard. The aim of the study is to treat the lesion with a device that works both with cold and radiofrequency. The device is already in use for the treatment of lesions. The device allows direct treatment of the lesion during the routine bronchoscopy. As planned, the lesion will then be surgically removed. After the surgery the lesion will be analyzed in the pathology to show the effect of the use of the device. This additional treatment is safe and will support the treatment of the lesion. There are no additional steps or assessments for the participants to undergo.",[57,58,25],"NSCLC","Cryotherapy",[60],"Tumor Staging and Resection","NOT_YET_RECRUITING","2026-04-07",{"date":64,"type":34},"2026-04-15",{"date":66,"type":20},"2026-05",{"date":68,"type":20},"2028-10",{"name":70,"class":41},"Elisabethinen Hospital"]